Stryker Reports Strong Q2 Earnings Amid Recovery and Operational Improvements
On July 30, 2026, Stryker (SYK) released its second-quarter earnings report showing strong performance across multiple business segments. The company reported a 9% increase in organic net sales driven by recovery from a prior cybersecurity incident and increased production to meet demand. Adjusted EPS rose 17.9% year-over-year to $3.69, supported by improved gross margins and operational execution. Key growth was observed across MedSurg, Orthopaedics, Medical US, Trauma, Endoscopy, Instruments, and US Knees segments. However, the Vascular segment saw a 6.7% decline due to supply disruptions in its peripheral vascular business leading to backorders. Stryker also updated full-year guidance for organic net sales growth between 8.3% and 9.3%, with adjusted EPS expected to range from $14.95 to $15.10. The company ended the quarter with $3.5 billion in cash and marketable securities, plans to resume share repurchases under a $1 billion authorization, and noted ongoing costs related to IT stabilization following cybersecurity issues.
Tickers: $SYK
Topics: financial_performance operational_metrics sales_growth